Exploring the Mechanisms and Therapeutic Approaches of Mitochondrial Dysfunction in Alzheimer's Disease: An Educational Literature Review.
Alzheimer’s Disease
Mitochondrial Dysfunction
Therapeutic Modalities
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
received:
30
01
2024
accepted:
30
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
10
9
2024
Statut:
aheadofprint
Résumé
Alzheimer's disease (AD) presents a significant challenge to global health. It is characterized by progressive cognitive deterioration and increased rates of morbidity and mortality among older adults. Among the various pathophysiologies of AD, mitochondrial dysfunction, encompassing conditions such as increased reactive oxygen production, dysregulated calcium homeostasis, and impaired mitochondrial dynamics, plays a pivotal role. This review comprehensively investigates the mechanisms of mitochondrial dysfunction in AD, focusing on aspects such as glucose metabolism impairment, mitochondrial bioenergetics, calcium signaling, protein tau and amyloid-beta-associated synapse dysfunction, mitophagy, aging, inflammation, mitochondrial DNA, mitochondria-localized microRNAs, genetics, hormones, and the electron transport chain and Krebs cycle. While lecanemab is the only FDA-approved medication to treat AD, we explore various therapeutic modalities for mitigating mitochondrial dysfunction in AD, including antioxidant drugs, antidiabetic agents, acetylcholinesterase inhibitors (FDA-approved to manage symptoms), nutritional supplements, natural products, phenylpropanoids, vaccines, exercise, and other potential treatments.
Identifiants
pubmed: 39254911
doi: 10.1007/s12035-024-04468-y
pii: 10.1007/s12035-024-04468-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Alkon D, Sun MK, Thompson R (2021) Evidence of significant cognitive improvement over baseline in advanced Alzheimer’s disease (AD) patients: a regenerative therapeutic strategy. Alzheimers Dement 17(S9):e050013
doi: 10.1002/alz.050013
Kashif M, Sivaprakasam P, Vijendra P, Waseem M, Pandurangan AK (2023) A recent update on pathophysiology and therapeutic interventions of Alzheimer’s disease. Curr Pharm Des. https://doi.org/10.2174/0113816128264355231121064704
Varadharajan A, Davis AD, Ghosh A, Jagtap T, Xavier A, Menon AJ et al (2023) Guidelines for pharmacotherapy in Alzheimer’s disease – a primer on FDA-approved drugs. J Neurosci Rural Pract 14(4):566–573
pubmed: 38059250
pmcid: 10696336
doi: 10.25259/JNRP_356_2023
Gettman L (2024) Lecanemab-irmb (Leqembi™) for treatment of Alzheimer’s disease. Sr Care Pharm 39(2):75–77
pubmed: 38263569
doi: 10.4140/TCP.n.2024.75
Huang M, Bargues-Carot A, Riaz Z, Wickham H, Zenitsky G, Jin H et al (2022) Impact of environmental risk factors on mitochondrial dysfunction, neuroinflammation, protein misfolding, and oxidative stress in the etiopathogenesis of Parkinson’s disease. Int J Mol Sci 23(18):10808
pubmed: 36142718
pmcid: 9505762
doi: 10.3390/ijms231810808
Nabi SU, Khan A, Siddiqui EM, Rehman MU, Alshahrani S, Arafah A et al (2022) Mechanisms of mitochondrial malfunction in Alzheimer’s disease: new therapeutic hope. Oxid Med Cell Longev 2022:4759963
pubmed: 35607703
pmcid: 9124149
doi: 10.1155/2022/4759963
Joshi M, Joshi S, Khambete M, Degani M (2023) Role of calcium dysregulation in Alzheimer’s disease and its therapeutic implications. Chem Biol Drug Des 101(2):453–468
pubmed: 36373976
doi: 10.1111/cbdd.14175
Mani S, Swargiary G, Singh M, Agarwal S, Dey A, Ojha S et al (2021) Mitochondrial defects: an emerging theranostic avenue towards Alzheimer’s associated dysregulations. Life Sci 15(285):119985
doi: 10.1016/j.lfs.2021.119985
Fracassi A, Marcatti M, Zolochevska O, Tabor N, Woltjer R, Moreno S et al (2021) Oxidative damage and antioxidant response in frontal cortex of demented and nondemented individuals with Alzheimer’s neuropathology. J Neurosci Off J Soc Neurosci 41(3):538–554
doi: 10.1523/JNEUROSCI.0295-20.2020
Du H, Guo L, Yan SS (2012) Synaptic mitochondrial pathology in Alzheimer’s disease. Antioxid Redox Signal 16(12):1467–1475
pubmed: 21942330
pmcid: 3329948
doi: 10.1089/ars.2011.4277
Manczak M, Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21(11):2538–2547
pubmed: 22367970
pmcid: 3349426
doi: 10.1093/hmg/dds072
Tranah GJ, Nalls MA, Katzman SM, Yokoyama JS, Lam ET, Zhao Y et al (2012) Mitochondrial DNA sequence variation associated with dementia and cognitive function in the elderly. J Alzheimers Dis JAD 32(2):357–372
pubmed: 22785396
doi: 10.3233/JAD-2012-120466
Perez Ortiz JM, Swerdlow RH (2019) Mitochondrial dysfunction in Alzheimer’s disease: role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol 176(18):3489–3507
pubmed: 30675901
pmcid: 6715612
doi: 10.1111/bph.14585
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH et al (2021) The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry 26(10):5481–5503
pubmed: 34456336
pmcid: 8758495
doi: 10.1038/s41380-021-01249-0
Brucato FH, Benjamin DE (2020) Synaptic pruning in Alzheimer’s disease: role of the complement system. Glob J Med Res 29:1–20
Paasila PJ, Aramideh JA, Sutherland GT, Graeber MB (2022) Synapses, microglia, and lipids in Alzheimer’s disease. Front Neurosci 12(15):778822
doi: 10.3389/fnins.2021.778822
Rather MA, Khan A, Alshahrani S, Rashid H, Qadri M, Rashid S et al (2021) Inflammation and Alzheimer’s disease: mechanisms and therapeutic implications by natural products. Oliveira SHP, editor. Mediators Inflamm 2021:1–21. https://doi.org/10.1155/2021/9982954
Ramachandran AK, Das S, Joseph A, Shenoy GG, Alex AT, Mudgal J (2021) Neurodegenerative pathways in Alzheimer’s disease: a review. Curr Neuropharmacol 19(5):679–692
pubmed: 32851951
pmcid: 8573750
doi: 10.2174/1570159X18666200807130637
Chen ZR, Huang JB, Yang SL, Hong FF (2022) Role of cholinergic signaling in Alzheimer’s disease. Mol Basel Switz 27(6):1816
Wong KY, Roy J, Fung ML, Heng BC, Zhang C, Lim LW (2020) Relationships between mitochondrial dysfunction and neurotransmission failure in Alzheimer’s disease. Aging Dis 11(5):1291–1316
pubmed: 33014538
pmcid: 7505271
doi: 10.14336/AD.2019.1125
Tyagi S, Thakur AK (2023) Neuropharmacological study on capsaicin in scopolamine-injected mice. Curr Alzheimer Res 20(9):660–676
pubmed: 38213170
doi: 10.2174/0115672050286225231230130613
Aldossary AM, Tawfik EA, Alomary MN, Alsudir SA, Alfahad AJ, Alshehri AA et al (2022) Recent advances in mitochondrial diseases: from molecular insights to therapeutic perspectives. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc 30(8):1065–1078
Onyango IG, Bennett JP, Stokin GB (2021) Mitochondrially-targeted therapeutic strategies for Alzheimer’s disease. Curr Alzheimer Res 18(10):753–771
pubmed: 34879805
pmcid: 9178515
doi: 10.2174/1567205018666211208125855
Wang W, Zhao F, Ma X, Perry G, Zhu X (2020) Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener 15(1):30
pubmed: 32471464
pmcid: 7257174
doi: 10.1186/s13024-020-00376-6
Bélanger M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14(6):724–738
pubmed: 22152301
doi: 10.1016/j.cmet.2011.08.016
Zheng PP, Romme E, van der Spek PJ, Dirven CMF, Willemsen R, Kros JM (2010) Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Ann Neurol 68(6):835–844
pubmed: 21194153
doi: 10.1002/ana.22318
Kapogiannis D, Mattson MP (2011) Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol 10(2):187–198
pubmed: 21147038
doi: 10.1016/S1474-4422(10)70277-5
Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H et al (2013) Glucose levels and risk of dementia. N Engl J Med 369(6):540–548
pubmed: 23924004
pmcid: 3955123
doi: 10.1056/NEJMoa1215740
Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N et al (2018) A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer’s disease. Exp Gerontol 1(107):18–26
doi: 10.1016/j.exger.2017.07.004
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S et al (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol 17(3):241–250
pubmed: 29397305
pmcid: 5816717
doi: 10.1016/S1474-4422(18)30028-0
Paranjpe MD, Chen X, Liu M, Paranjpe I, Leal JP, Wang R et al (2019) The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. NeuroImage Clin 1(22):101795
doi: 10.1016/j.nicl.2019.101795
Mount DL, Ashley AV, Lah JJ, Levey AI, Goldstein FC (2009) Is ApoE ε4 Associated with cognitive functioning in african americans diagnosed with alzheimer disease? an exploratory study. South Med J 102(9):890. https://doi.org/10.1097/SMJ.0b013e3181b21b82
doi: 10.1097/SMJ.0b013e3181b21b82
pubmed: 19668025
pmcid: 4406227
Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C, Ogunniyi A et al (2014) APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba. Int Psychogeriatr 26(6):977–985
pubmed: 24565289
pmcid: 4012422
doi: 10.1017/S1041610214000167
Mortimer JA, Snowdon DA, Markesbery WR (2009) The effect of APOE-ε4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord 23(2):152
pubmed: 19484916
pmcid: 2752689
doi: 10.1097/WAD.0b013e318190a855
Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W et al (2014) Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82(20):1760–1767
pubmed: 24748674
pmcid: 4035706
doi: 10.1212/WNL.0000000000000431
Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC et al (2018) Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. Brain 141(6):1828–1839
pubmed: 29672664
pmcid: 5972633
doi: 10.1093/brain/awy103
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D et al (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci101(1):284–289
Chen Z, Zhong C (2013) Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 1(108):21–43
doi: 10.1016/j.pneurobio.2013.06.004
Weise CM, Chen K, Chen Y, Kuang X, Savage CR, Reiman EM (2018) Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. NeuroImage Clin 1(20):286–296
doi: 10.1016/j.nicl.2018.07.016
Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J et al (2018) Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging 45(9):1497–1508
pubmed: 29704037
doi: 10.1007/s00259-018-4039-7
Sörensen A, Blazhenets G, Rücker G, Schiller F, Meyer PT, Frings L (2019) Prognosis of conversion of mild cognitive impairment to Alzheimer’s dementia by voxel-wise Cox regression based on FDG PET data. NeuroImage Clin 1(21):101637
doi: 10.1016/j.nicl.2018.101637
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V et al (2018) Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91(14):e1295–e1306
pubmed: 30217935
pmcid: 6177272
doi: 10.1212/WNL.0000000000006277
Benzinger TLS, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C et al (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci 110(47):E4502–E4509
Altmann A, Ng B, Landau SM, Jagust WJ, Greicius MD, for the Alzheimer’s Disease Neuroimaging Initiative (2015) Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain 138(12):3734–3746
Mastroeni D, Khdour OM, Delvaux E, Nolz J, Olsen G, Berchtold N et al (2017) Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer’s disease. Alzheimers Dement 13(5):510–519
pubmed: 27793643
doi: 10.1016/j.jalz.2016.09.003
Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A et al (2008) Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci 105(11):4441–4416
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42(1):85–94
pubmed: 9225689
doi: 10.1002/ana.410420114
Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S et al (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 334(12):752–758
pubmed: 8592548
doi: 10.1056/NEJM199603213341202
Brooks WM, Lynch PJ, Ingle CC, Hatton A, Emson PC, Faull RLM et al (2007) Gene expression profiles of metabolic enzyme transcripts in Alzheimer’s disease. Brain Res 5(1127):127–135
doi: 10.1016/j.brainres.2006.09.106
Burgoyne RD, Haynes LP (2012) Understanding the physiological roles of the neuronal calcium sensor proteins. Mol Brain 5(1):2
pubmed: 22269068
pmcid: 3271974
doi: 10.1186/1756-6606-5-2
Gleichmann M, Mattson MP (2011) Neuronal calcium homeostasis and dysregulation. Antioxid Redox Signal 14(7):1261–1273
pubmed: 20626318
pmcid: 3048837
doi: 10.1089/ars.2010.3386
Mochida S (2021) Neurotransmitter release site replenishment and presynaptic plasticity. Int J Mol Sci 22(1):327
doi: 10.3390/ijms22010327
Kannurpatti SS (2017) Mitochondrial calcium homeostasis: implications for neurovascular and neurometabolic coupling. J Cereb Blood Flow Metab 37(2):381–395
pubmed: 27879386
doi: 10.1177/0271678X16680637
Pedriali G, Rimessi A, Sbano L, Giorgi C, Wieckowski MR, Previati M, Pinton P (2017) Regulation of endoplasmic reticulum-mitochondria Ca2+ transfer and its importance for anti-cancer therapies. Front Oncol 7:286744. https://doi.org/10.3389/fonc.2017.00180
Reddy PH (2013) Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer’s disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta BBA - Mol Basis Dis 1832(12):1913–1921
doi: 10.1016/j.bbadis.2013.06.012
Reddy PH (2013) Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer’s disease? Biochim Biophys Acta BBA - Mol Basis Dis 1832(1):67–75
doi: 10.1016/j.bbadis.2012.09.003
Finkel T, Menazza S, Holmström KM, Parks RJ, Liu J, Sun J et al (2015) The ins and outs of mitochondrial calcium. Circ Res 116(11):1810–1819
pubmed: 25999421
pmcid: 6296495
doi: 10.1161/CIRCRESAHA.116.305484
Shoshan-Barmatz V, De S (2017) Mitochondrial VDAC, the Na+/Ca2+ exchanger, and the Ca2+ uniporter in Ca2+ dynamics and signaling. In: Krebs J (eds) Membrane dynamics and calcium signaling. Advances in experimental medicine and biology, vol 981. Springer, Cham. https://doi.org/10.1007/978-3-319-55858-5_13
Calvo-Rodriguez M, Hou SS, Snyder AC, Kharitonova EK, Russ AN, Das S et al (2020) Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease. Nat Commun 11(1):2146
pubmed: 32358564
pmcid: 7195480
doi: 10.1038/s41467-020-16074-2
Green KN (2009) Calcium in the initiation, progression and as an effector of Alzheimer’s disease pathology. J Cell Mol Med 13(9a):2787–2799
pubmed: 19650832
pmcid: 4498936
doi: 10.1111/j.1582-4934.2009.00861.x
Tillement L, Lecanu L, Papadopoulos V (2011) Alzheimer’s disease: effects of β-amyloid on mitochondria. Mitochondrion 11(1):13–21
pubmed: 20817045
doi: 10.1016/j.mito.2010.08.009
Berridge MJ (2014) Calcium regulation of neural rhythms, memory and Alzheimer’s disease. J Physiol 592(2):281–293
pubmed: 23753528
doi: 10.1113/jphysiol.2013.257527
Britti E, Delaspre F, Tamarit J, Ros J (2018) Mitochondrial calcium signalling and neurodegenerative diseases. Neuronal Signal 2(4):NS20180061
pubmed: 32714593
pmcid: 7373239
doi: 10.1042/NS20180061
John A, Reddy PH (2021) Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev 1(65):101208
doi: 10.1016/j.arr.2020.101208
Morton H, Kshirsagar S, Orlov E, Bunquin LE, Sawant N, Boleng L et al (2021) Defective mitophagy and synaptic degeneration in Alzheimer’s disease: focus on aging, mitochondria and synapse. Free Radic Biol Med 20(172):652–667
doi: 10.1016/j.freeradbiomed.2021.07.013
Chen Y, Fu AKY, Ip NY (2019) Synaptic dysfunction in Alzheimer’s disease: mechanisms and therapeutic strategies. Pharmacol Ther 1(195):186–198
doi: 10.1016/j.pharmthera.2018.11.006
Rajmohan R, Reddy PH (2017) Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease Neurons. J Alzheimers Dis 57(4):975–999
pubmed: 27567878
pmcid: 5793225
doi: 10.3233/JAD-160612
Calkins MJ, Reddy PH (2011) Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons. Biochim Biophys Acta BBA - Mol Basis Dis 1812(4):507–513
doi: 10.1016/j.bbadis.2011.01.007
Tu S, Okamoto S ichi, Lipton SA, Xu H (2014) Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener 9(1):48
Marsh J, Alifragis P (2018) Synaptic dysfunction in Alzheimer’s disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regen Res 13(4):616
pubmed: 29722304
pmcid: 5950662
doi: 10.4103/1673-5374.230276
Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ et al (2017) Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun 8(1):15295
pubmed: 28492240
pmcid: 5437271
doi: 10.1038/ncomms15295
McInnes J, Wierda K, Snellinx A, Bounti L, Wang YC, Stancu IC et al (2018) Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron 97(4):823-835.e8
pubmed: 29398363
doi: 10.1016/j.neuron.2018.01.022
Dixit R, Ross JL, Goldman YE, Holzbaur ELF (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science 319(5866):1086–1089
pubmed: 18202255
pmcid: 2866193
doi: 10.1126/science.1152993
Cheng Y, Bai F (2018) The association of Tau with mitochondrial dysfunction in Alzheimer's disease. Front Neurosci 12:320523. https://doi.org/10.3389/fnins.2018.00163
Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Strooper B et al (2015) Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep 11(8):1176–1183
pubmed: 25981034
doi: 10.1016/j.celrep.2015.04.043
Gowda P, Reddy PH, Kumar S (2022) Deregulated mitochondrial microRNAs in Alzheimer’s disease: focus on synapse and mitochondria. Ageing Res Rev 1(73):101529
doi: 10.1016/j.arr.2021.101529
Bell SM, Barnes K, De Marco M, Shaw PJ, Ferraiuolo L, Blackburn DJ et al (2021) Mitochondrial dysfunction in Alzheimer’s disease: a biomarker of the future? Biomedicines 9(1):63
pubmed: 33440662
pmcid: 7827030
doi: 10.3390/biomedicines9010063
Cai Q, Jeong YY (2020) Mitophagy in Alzheimer’s disease and other age-related neurodegenerative diseases. Cells 9(1):150
pubmed: 31936292
pmcid: 7017092
doi: 10.3390/cells9010150
Corsetti V, Florenzano F, Atlante A, Bobba A, Ciotti MT, Natale F et al (2015) NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer’s disease. Hum Mol Genet 24(11):3058–3081
pubmed: 25687137
doi: 10.1093/hmg/ddv059
Cummins N, Tweedie A, Zuryn S, Bertran-Gonzalez J, Götz J (2019) Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J 38(3):e99360
pubmed: 30538104
doi: 10.15252/embj.201899360
Hu Y, Li XC, Wang Z-H, Luo Y, Zhang X, Liu XP et al (2016) Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget 7(14):17356–68
pubmed: 26943044
pmcid: 4951217
doi: 10.18632/oncotarget.7861
Monteiro-Cardoso VF, Oliveira MM, Melo T, Domingues MRM, Moreira PI, Ferreiro E et al (2015) Cardiolipin profile changes are associated to the early synaptic mitochondrial dysfunction in Alzheimer’s disease. J Alzheimers Dis JAD 43(4):1375–1392
pubmed: 25182746
doi: 10.3233/JAD-141002
Ye X, Sun X, Starovoytov V, Cai Q (2015) Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer’s disease patient brains. Hum Mol Genet 24(10):2938–2951
pubmed: 25678552
pmcid: 4406302
doi: 10.1093/hmg/ddv056
Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M et al (2004) Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol 63(8):821–830
pubmed: 15330337
doi: 10.1093/jnen/63.8.821
Ji ZS, Müllendorff K, Cheng IH, Miranda RD, Huang Y, Mahley RW (2006) Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration. J Biol Chem 281(5):2683–2692
pubmed: 16298992
doi: 10.1074/jbc.M506646200
Bernardi P (2013) The mitochondrial permeability transition pore: a mystery solved? Front Physiol 4:95
pubmed: 23675351
pmcid: 3650560
doi: 10.3389/fphys.2013.00095
Pérez MJ, Ponce DP, Aranguiz A, Behrens MI, Quintanilla RA (2018) Mitochondrial permeability transition pore contributes to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer’s disease. Redox Biol 19:290–300
pubmed: 30199818
pmcid: 6129674
doi: 10.1016/j.redox.2018.09.001
Sharma C, Kim S, Nam Y, Jung UJ, Kim SR (2021) Mitochondrial dysfunction as a driver of cognitive impairment in Alzheimer’s disease. Int J Mol Sci 22(9):4850
pubmed: 34063708
pmcid: 8125007
doi: 10.3390/ijms22094850
Supnet C, Bezprozvanny I (2010) The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 47(2):183–189
pubmed: 20080301
pmcid: 2834825
doi: 10.1016/j.ceca.2009.12.014
Harada CN, Natelson Love MC, Triebel KL (2013) Normal cognitive aging. Clin Geriatr Med 29(4):737–752
pubmed: 24094294
pmcid: 4015335
doi: 10.1016/j.cger.2013.07.002
Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11(2):111–128
pubmed: 19585947
pmcid: 3181909
doi: 10.31887/DCNS.2009.11.2/cqiu
Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C et al (2009) Age, neuropathology, and dementia. N Engl J Med 360(22):2302–2309
pubmed: 19474427
doi: 10.1056/NEJMoa0806142
Payne BAI, Chinnery PF (2015) Mitochondrial dysfunction in aging: much progress but many unresolved questions. Biochim Biophys Acta 1847(11):1347–1353
pubmed: 26050973
pmcid: 4580208
doi: 10.1016/j.bbabio.2015.05.022
Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11(3):298–300
pubmed: 13332224
doi: 10.1093/geronj/11.3.298
Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809):239–247
pubmed: 11089981
doi: 10.1038/35041687
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194–1217
pubmed: 23746838
pmcid: 3836174
doi: 10.1016/j.cell.2013.05.039
Nisbet RM, Polanco JC, Ittner LM, Götz J (2015) Tau aggregation and its interplay with amyloid-β. Acta Neuropathol (Berl) 129(2):207–220
pubmed: 25492702
doi: 10.1007/s00401-014-1371-2
Meyer A, Laverny G, Bernardi L, Charles AL, Alsaleh G, Pottecher J et al (2018) Mitochondria: an organelle of bacterial origin controlling inflammation. Front Immunol 19(9):536
doi: 10.3389/fimmu.2018.00536
Wilkins HM, Carl SM, Greenlief ACS, Festoff BW, Swerdlow RH (2014) Bioenergetic dysfunction and inflammation in Alzheimer’s disease: a possible connection. Front Aging Neurosci 6:311
pubmed: 25426068
pmcid: 4226164
doi: 10.3389/fnagi.2014.00311
Bajwa E, Pointer CB, Klegeris A (2019) The role of mitochondrial damage-associated molecular patterns in chronic neuroinflammation. Mediators Inflamm 2019:4050796
pubmed: 31065234
pmcid: 6466851
doi: 10.1155/2019/4050796
Wilkins HM, Koppel SJ, Weidling IW, Roy N, Ryan LN, Stanford JA et al (2016) Extracellular mitochondria and mitochondrial components act as damage-associated molecular pattern molecules in the mouse brain. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 11(4):622–628
doi: 10.1007/s11481-016-9704-7
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368(2):117–127
pubmed: 23150934
doi: 10.1056/NEJMoa1211851
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160(6):1061–1071
pubmed: 25728668
pmcid: 4477963
doi: 10.1016/j.cell.2015.01.049
Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L et al (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol Baltim Md 1950 177(6):3520–4
Jiang T, Zhang YD, Chen Q, Gao Q, Zhu XC, Zhou JS et al (2016) TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology 105:196–206
pubmed: 26802771
doi: 10.1016/j.neuropharm.2016.01.028
Yan MH, Wang X, Zhu X (2013) Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 62:90–101
pubmed: 23200807
doi: 10.1016/j.freeradbiomed.2012.11.014
Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA (2005) Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J Neurochem 93(4):953–962
pubmed: 15857398
doi: 10.1111/j.1471-4159.2005.03053.x
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS et al (2001) Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci Off J Soc Neurosci 21(9):3017–3023
doi: 10.1523/JNEUROSCI.21-09-03017.2001
Krishnan KJ, Ratnaike TE, De Gruyter HLM, Jaros E, Turnbull DM (2012) Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer’s disease. Neurobiol Aging 33(9):2210–2214
pubmed: 21925769
doi: 10.1016/j.neurobiolaging.2011.08.009
Chen Y, Liu C, Parker WD, Chen H, Beach TG, Liu X et al (2016) Mitochondrial DNA rearrangement spectrum in brain tissue of Alzheimer’s disease: analysis of 13 cases. PLoS ONE 11(6):e0154582
pubmed: 27299301
pmcid: 4907522
doi: 10.1371/journal.pone.0154582
Mancuso M, Calsolaro V, Orsucci D, Carlesi C, Choub A, Piazza S et al (2009) Mitochondria, cognitive impairment, and Alzheimer’s disease. Int J Alzheimers Dis 6(2009):951548
Blanch M, Mosquera JL, Ansoleaga B, Ferrer I, Barrachina M (2016) Altered mitochondrial DNA methylation pattern in Alzheimer disease-related pathology and in Parkinson disease. Am J Pathol 186(2):385–397
pubmed: 26776077
doi: 10.1016/j.ajpath.2015.10.004
Stoccoro A, Siciliano G, Migliore L, Coppedè F (2017) Decreased methylation of the mitochondrial D-loop region in late-onset Alzheimer’s disease. J Alzheimers Dis JAD 59(2):559–564
pubmed: 28655136
doi: 10.3233/JAD-170139
Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T et al (2012) Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485(7397):251–255
pubmed: 22535248
pmcid: 3378041
doi: 10.1038/nature10992
Simoncini C, Orsucci D, Caldarazzo Ienco E, Siciliano G, Bonuccelli U, Mancuso M (2015) Alzheimer’s pathogenesis and its link to the mitochondrion. Oxid Med Cell Longev 2015:803942
pubmed: 25973139
pmcid: 4417983
doi: 10.1155/2015/803942
Zhang L, Fang Y, Zhao X, Zheng Y, Ma Y, Li S et al (2021) miR-204 silencing reduces mitochondrial autophagy and ROS production in a murine AD model via the TRPML1-activated STAT3 pathway. Mol Ther Nucleic Acids 4(24):822–831
doi: 10.1016/j.omtn.2021.02.010
Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish JZ, Simpkins JW (2016) Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res 1(1646):139–151
doi: 10.1016/j.brainres.2016.05.026
Chen FZ, Zhao Y, Chen HZ (2019) MicroRNA-98 reduces amyloid β-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer’s disease mice. Int J Mol Med 43(1):91–102
pubmed: 30365070
Lang A, Grether-Beck S, Singh M, Kuck F, Jakob S, Kefalas A et al (2016) MicroRNA-15b regulates mitochondrial ROS production and the senescence-associated secretory phenotype through sirtuin 4/SIRT4. Aging 8(3):484–505
pubmed: 26959556
pmcid: 4833141
doi: 10.18632/aging.100905
Remenyi J, van den Bosch MWM, Palygin O, Mistry RB, McKenzie C, Macdonald A et al (2013) miR-132/212 knockout mice reveal roles for these miRNAs in regulating cortical synaptic transmission and plasticity. PLoS ONE 8(4):e62509
pubmed: 23658634
pmcid: 3637221
doi: 10.1371/journal.pone.0062509
Wingo TS, Yang J, Fan W, Min Canon S, Gerasimov ES, Lori A et al (2020) Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia. NPJ Genomic Med 5:6
doi: 10.1038/s41525-019-0113-8
Di Rita A, Maiorino T, Bruqi K, Volpicelli F, Bellenchi GC, Strappazzon F (2020) miR-218 inhibits mitochondrial clearance by targeting PRKN E3 ubiquitin ligase. Int J Mol Sci 21(1):355
pubmed: 31948106
pmcid: 6981953
doi: 10.3390/ijms21010355
Chaudhuri AD, Choi DC, Kabaria S, Tran A, Junn E (2016) MicroRNA-7 regulates the function of mitochondrial permeability transition pore by targeting VDAC1 expression. J Biol Chem 291(12):6483–6493
pubmed: 26801612
pmcid: 4813563
doi: 10.1074/jbc.M115.691352
Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P (2010) miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLOS Genet 6(1):e1000795
pubmed: 20062521
pmcid: 2793031
doi: 10.1371/journal.pgen.1000795
Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S (2022) Neuronal cell death mechanisms in Alzheimer’s disease: an insight. Front Mol Neurosci 15:937133
pubmed: 36090249
pmcid: 9454331
doi: 10.3389/fnmol.2022.937133
Swerdlow RH (2007) Is aging part of Alzheimer’s disease, or is Alzheimer’s disease part of aging? Neurobiol Aging 28(10):1465–1480
pubmed: 16876913
doi: 10.1016/j.neurobiolaging.2006.06.021
Blacker D, Tanzi RE (1998) The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 55(3):294–296
pubmed: 9520001
doi: 10.1001/archneur.55.3.294
Gaignard P, Liere P, Thérond P, Schumacher M, Slama A, Guennoun R (2017) Role of sex hormones on brain mitochondrial function, with special reference to aging and neurodegenerative diseases. Front Aging Neurosci 9:406
pubmed: 29270123
pmcid: 5725410
doi: 10.3389/fnagi.2017.00406
Guevara R, Gianotti M, Roca P, Oliver J (2011) Age and sex-related changes in rat brain mitochondrial function. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 27(3–4):201–206
doi: 10.1159/000327945
Lejri I, Grimm A, Eckert A (2018) Mitochondria, estrogen and female brain aging. Front Aging Neurosci 10:341477. https://doi.org/10.3389/fnagi.2018.00124
Zhao W, Hou Y, Song X, Wang L, Zhang F, Zhang H et al (2021) Estrogen deficiency induces mitochondrial damage prior to emergence of cognitive deficits in a postmenopausal mouse model. Front Aging Neurosci 13:713819
pubmed: 34335235
pmcid: 8319728
doi: 10.3389/fnagi.2021.713819
Gaignard P, Fréchou M, Schumacher M, Thérond P, Mattern C, Slama A et al (2016) Progesterone reduces brain mitochondrial dysfunction after transient focal ischemia in male and female mice. J Cereb Blood Flow Metab 36(3):562–568
pubmed: 26661198
doi: 10.1177/0271678X15610338
Yan W, Kang Y, Ji X, Li S, Li Y, Zhang G et al (2017) Testosterone upregulates the expression of mitochondrial ND1 and ND4 and alleviates the oxidative damage to the nigrostriatal dopaminergic system in orchiectomized rats. Oxid Med Cell Longev 2017:1202459
pubmed: 29138672
pmcid: 5613679
doi: 10.1155/2017/1202459
Parker WD, Parks J, Filley CM, Kleinschmidt-DeMasters BK (1994) Electron transport chain defects in Alzheimer’s disease brain. Neurology 44(6):1090–1096
pubmed: 8208407
doi: 10.1212/WNL.44.6.1090
Cottrell DA, Blakely EL, Johnson MA, Ince PG, Turnbull DM (2001) Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57(2):260–264
pubmed: 11468310
doi: 10.1212/WNL.57.2.260
Maurer I, Zierz S, Möller H (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21(3):455–462
pubmed: 10858595
doi: 10.1016/S0197-4580(00)00112-3
Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer’s disease. J Neurochem 63(6):2179–2184
pubmed: 7964738
doi: 10.1046/j.1471-4159.1994.63062179.x
Mastrogiacoma F, Lindsay JG, Bettendorff L, Rice J, Kish SJ (1996) Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. Ann Neurol 39(5):592–598
pubmed: 8619544
doi: 10.1002/ana.410390508
Gibson GE, Park LC, Sheu KF, Blass JP, Calingasan NY (2000) The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem Int 36(2):97–112
pubmed: 10676873
doi: 10.1016/S0197-0186(99)00114-X
Ko LW, Sheu KF, Thaler HT, Markesbery WR, Blass JP (2001) Selective loss of KGDHC-enriched neurons in Alzheimer temporal cortex: does mitochondrial variation contribute to selective vulnerability? J Mol Neurosci MN 17(3):361–369
pubmed: 11859932
doi: 10.1385/JMN:17:3:361
Abudhaise H, Taanman JW, DeMuylder P, Fuller B, Davidson BR (2021) Mitochondrial respiratory chain and Krebs cycle enzyme function in human donor livers subjected to end-ischaemic hypothermic machine perfusion. PLoS ONE 16(10):e0257783
pubmed: 34710117
pmcid: 8553115
doi: 10.1371/journal.pone.0257783
Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57(5):695–703
pubmed: 15852400
doi: 10.1002/ana.20474
Schulman MP, Richert DA (1957) Heme synthesis in vitamin B6 and pantothenic acid deficiencies. J Biol Chem 226(1):181–189
pubmed: 13428751
doi: 10.1016/S0021-9258(18)64819-7
Furuyama K, Sassa S (2000) Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J Clin Invest 105(6):757–764
pubmed: 10727444
pmcid: 377455
doi: 10.1172/JCI6816
Atamna H, Frey WH (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease. Mitochondrion 7(5):297–310
pubmed: 17625988
doi: 10.1016/j.mito.2007.06.001
Atamna H, Newberry J, Erlitzki R, Schultz CS, Ames BN (2007) Biotin deficiency inhibits heme synthesis and impairs mitochondria in human lung fibroblasts. J Nutr 137(1):25–30
pubmed: 17182796
doi: 10.1093/jn/137.1.25
Song Y, Zhu XY, Zhang XM, Xiong H (2022) Targeted mitochondrial epigenetics: a new direction in Alzheimer’s disease treatment. Int J Mol Sci 23(17):9703
pubmed: 36077101
pmcid: 9456144
doi: 10.3390/ijms23179703
Eckert GP, Eckert SH, Eckmann J, Hagl S, Muller WE, Friedland K (2020) Olesoxime improves cerebral mitochondrial dysfunction and enhances Aβ levels in preclinical models of Alzheimer’s disease. Exp Neurol 329:113286
pubmed: 32199815
doi: 10.1016/j.expneurol.2020.113286
Grewal R, Reutzel M, Dilberger B, Hein H, Zotzel J, Marx S et al (2020) Purified oleocanthal and ligstroside protect against mitochondrial dysfunction in models of early Alzheimer’s disease and brain ageing. Exp Neurol 328:113248
pubmed: 32084452
doi: 10.1016/j.expneurol.2020.113248
Tu JL, Chen WP, Cheng ZJ, Zhang G, Luo QH, Li M et al (2020) EGb761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer’s disease. Brain Res 1(1736):146730
doi: 10.1016/j.brainres.2020.146730
Zhang XY, Meng Y, Yan XJ, Liu S, Wang GQ, Cao YP (2021) Immunization with Aβ3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer’s disease-like pathology in Tg-APPswe/PSEN1dE9 mice. Brain Res Bull 174:31–40
pubmed: 34044034
doi: 10.1016/j.brainresbull.2021.05.019
Lauretti E, Dincer O, Praticò D (2020) Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res 1867(5):118664
pubmed: 32006534
pmcid: 7047718
doi: 10.1016/j.bbamcr.2020.118664
Dai DF, Chiao YA, Martin GM, Marcinek DJ, Basisty N, Quarles EK et al (2017) Mitochondrial-targeted catalase: extended longevity and the roles in various disease models. Prog Mol Biol Transl Sci 146:203–241
pubmed: 28253986
doi: 10.1016/bs.pmbts.2016.12.015
McCormick B, Lowes DA, Colvin L, Torsney C, Galley HF (2016) MitoVitE, a mitochondria-targeted antioxidant, limits paclitaxel-induced oxidative stress and mitochondrial damage in vitro, and paclitaxel-induced mechanical hypersensitivity in a rat pain model. Br J Anaesth 117(5):659–666
pubmed: 27799181
doi: 10.1093/bja/aew309
Arlt S, Müller-Thomsen T, Beisiegel U, Kontush A (2012) Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease. Neurochem Res 37(12):2706–2714
pubmed: 22878647
doi: 10.1007/s11064-012-0860-8
Dong R, Yang Q, Zhang Y, Li J, Zhang L, Zhao H (2018) Meta-analysis of vitamin C, vitamin E and β-carotene levels in the plasma of Alzheimer’s disease patients. Wei Sheng Yan Jiu 47(4):648–654
pubmed: 30081996
Misrani A, Tabassum S, Yang L (2021) Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease. Front Aging Neurosci 13:617588. https://doi.org/10.3389/fnagi.2021.617588
Mao P, Manczak M, Calkins MJ, Truong Q, Reddy TP, Reddy AP et al (2012) Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer’s disease: implications for neuroprotection and lifespan extension. Hum Mol Genet 21(13):2973–2990
pubmed: 22492996
pmcid: 3373244
doi: 10.1093/hmg/dds128
Tardiolo G, Bramanti P, Mazzon E (2018) Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Mol Basel Switz 23(12):3305
Spindler M, Beal MF, Henchcliffe C (2009) Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 5:597–610
pubmed: 19966907
pmcid: 2785862
Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG (2023) Coenzyme Q10 and dementia: a systematic review. Antioxidants 12(2):533
pubmed: 36830090
pmcid: 9952341
doi: 10.3390/antiox12020533
Basile GA, Iannuzzo F, Xerra F, Genovese G, Pandolfo G, Cedro C et al (2023) Cognitive and mood effect of alpha-lipoic acid supplementation in a nonclinical elder sample: an open-label pilot study. Int J Environ Res Public Health 20(3):2358
pubmed: 36767724
pmcid: 9916195
doi: 10.3390/ijerph20032358
Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, Colica C et al (2013) The effect of lipoic acid therapy on cognitive functioning in patients with Alzheimer’s disease. J Neurodegener Dis 2013:454253
pubmed: 26316990
pmcid: 4437336
Tripathi AK, Ray AK, Mishra SK, Bishen SM, Mishra H, Khurana A (2023) Molecular and therapeutic insights of alpha-lipoic acid as a potential molecule for disease prevention. Rev Bras Farmacogn Orgao Of Soc Bras Farmacogn 33(2):272–287
doi: 10.1007/s43450-023-00370-1
Chen C, Yang C, Wang J, Huang X, Yu H, Li S et al (2021) Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease. J Pineal Res 71(4):e12774
pubmed: 34617321
doi: 10.1111/jpi.12774
O’Reilly JA, Lynch M (2012) Rosiglitazone improves spatial memory and decreases insoluble Aβ(1–42) in APP/PS1 mice. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol 7(1):140–144
doi: 10.1007/s11481-011-9282-7
Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 6(4):246–254
pubmed: 16446752
doi: 10.1038/sj.tpj.6500369
Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM et al (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res 8(5):592–606
pubmed: 21592048
doi: 10.2174/156720511796391935
Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW et al (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis JAD 19(4):1205–1219
pubmed: 20308787
doi: 10.3233/JAD-2010-1314
An J, Zhou Y, Zhang M, Xie Y, Ke S, Liu L et al (2019) Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer’s disease. Behav Brain Res 16(370):111932
doi: 10.1016/j.bbr.2019.111932
Xie Y, Zheng J, Li S, Li H, Zhou Y, Zheng W et al (2021) GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer’s disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway. Biochem Pharmacol 188:114578
pubmed: 33895160
doi: 10.1016/j.bcp.2021.114578
Liao W, Xu J, Li B, Ruan Y, Li T, Liu J (2021) Deciphering the roles of metformin in Alzheimer’s disease: a snapshot. Front Pharmacol 12:728315
pubmed: 35153733
doi: 10.3389/fphar.2021.728315
Vial G, Detaille D, Guigas B (2019) Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol 10:294
doi: 10.3389/fendo.2019.00294
Chen S, Gan D, Lin S, Zhong Y, Chen M, Zou X et al (2022) Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. Theranostics 12(6):2722–2740
pubmed: 35401820
pmcid: 8965502
doi: 10.7150/thno.71360
Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS et al (2017) Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab 25(2):463–471
pubmed: 28089566
pmcid: 5299044
doi: 10.1016/j.cmet.2016.12.009
Chen JL, Luo C, Pu D, Zhang GQ, Zhao YX, Sun Y et al (2019) Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance. Exp Neurol 311:44–56
pubmed: 30219731
doi: 10.1016/j.expneurol.2018.09.008
GBD 2016 Dementia Collaborators (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(1):88–106
Birks JS, Grimley EJ (2015) Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 4:CD001191
Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 6(6):CD001190
pubmed: 29923184
Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163(2):495–529
pubmed: 10833325
doi: 10.1006/exnr.2000.7397
Jelic V, Winblad B (2016) Alzheimer disease. Donepezil and nursing home placement–benefits and costs. Nat Rev Neurol 12(1):11–13
pubmed: 26714658
doi: 10.1038/nrneurol.2015.237
Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y et al (2009) Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin 25(11):2577–2587
pubmed: 19735164
doi: 10.1185/03007990903236731
Marder K (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind parallel-group, placebo controlled study. Curr Neurol Neurosci Rep 6(5):363–364
doi: 10.1007/s11910-996-0015-x
Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T et al (2015) EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 22(6):889–898
pubmed: 25808982
doi: 10.1111/ene.12707
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3):317–324
pubmed: 14734594
doi: 10.1001/jama.291.3.317
Bakchine S, Loft H (2007) Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis JAD 11(4):471–479
pubmed: 17656827
doi: 10.3233/JAD-2007-11409
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366(10):893–903
pubmed: 22397651
doi: 10.1056/NEJMoa1106668
Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L et al (2013) The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs 27(6):469–478
pubmed: 23733403
pmcid: 3680656
doi: 10.1007/s40263-013-0077-7
Religa D, Fereshtehnejad SM, Cermakova P, Edlund AK, Garcia-Ptacek S, Granqvist N et al (2015) SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS ONE 10(2):e0116538
pubmed: 25695768
pmcid: 4335024
doi: 10.1371/journal.pone.0116538
Mesulam M (2004) The cholinergic lesion of Alzheimer’s disease: pivotal factor or side show? Learn Mem Cold Spring Harb N 11(1):43–49
doi: 10.1101/lm.69204
Turnbull MT, Boskovic Z, Coulson EJ (2018) Acute down-regulation of BDNF signaling does not replicate exacerbated amyloid-β levels and cognitive impairment induced by cholinergic basal forebrain lesion. Front Mol Neurosci 11:51
pubmed: 29520217
pmcid: 5827359
doi: 10.3389/fnmol.2018.00051
Labrador-Espinosa MA, Silva-Rodríguez J, Reina-Castillo MI, Mir P, Grothe MJ (2023) Basal forebrain atrophy, cortical thinning, and amyloid-β status in Parkinson’s disease-related cognitive decline. Mov Disord Off J Mov Disord Soc 38(10):1871–1880
doi: 10.1002/mds.29564
Li DD, Zhang YH, Zhang W, Zhao P (2019) Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci 13:472
pubmed: 31156366
pmcid: 6529534
doi: 10.3389/fnins.2019.00472
Farlow M, Anand R, Messina J, Hartman R, Veach J (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 44(4):236–241
pubmed: 11096224
doi: 10.1159/000008243
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A et al (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57(3):489–495
pubmed: 11502918
doi: 10.1212/WNL.57.3.489
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA et al (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57(3):481–488
pubmed: 11502917
doi: 10.1212/WNL.57.3.481
Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E et al (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet Lond Engl 363(9427):2105–2115
doi: 10.1016/S0140-6736(04)16499-4
Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO (2005) A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 19(1):51–56
pubmed: 15383747
doi: 10.1159/000080972
Wattmo C, Londos E, Minthon L (2015) Longitudinal associations between survival in Alzheimer’s disease and cholinesterase inhibitor use, progression, and community-based services. Dement Geriatr Cogn Disord 40(5–6):297–310
pubmed: 26335053
doi: 10.1159/000437050
Vellas B, Hausner L, Frölich L, Cantet C, Gardette V, Reynish E et al (2012) Progression of Alzheimer disease in Europe: data from the European ICTUS study. Curr Alzheimer Res 9(8):902–912
pubmed: 22742853
doi: 10.2174/156720512803251066
Wallin AK, Andreasen N, Eriksson S, Båtsman S, Nasman B, Ekdahl A et al (2007) Donepezil in Alzheimer’s disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 23(3):150–160
pubmed: 17312368
doi: 10.1159/000098052
Wattmo C, Londos E, Minthon L (2018) Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement. Curr Alzheimer Res 15(10):905–916
pubmed: 29732972
pmcid: 6174634
doi: 10.2174/1567205015666180507105326
Xu H, Garcia-Ptacek S, Jönsson L, Wimo A, Nordström P, Eriksdotter M (2021) Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology 96(17):e2220–e2230
pubmed: 33741639
pmcid: 8166426
doi: 10.1212/WNL.0000000000011832
Wattmo C, Londos E, Minthon L (2014) Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease. BMC Neurol 10(14):173
doi: 10.1186/s12883-014-0173-4
Tan ECK, Johnell K, Garcia-Ptacek S, Haaksma ML, Fastbom J, Bell JS et al (2018) Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia. Alzheimers Dement J Alzheimers Assoc 14(7):944–951
doi: 10.1016/j.jalz.2018.02.011
Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur Heart J 34(33):2585–2591
pubmed: 23735859
doi: 10.1093/eurheartj/eht182
Lin YT, Wu PH, Chen CS, Yang YH, Yang YH (2016) Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia. Sci Rep 5(6):29266
doi: 10.1038/srep29266
Corona C, Frazzini V, Silvestri E, Lattanzio R, Sorda RL, Piantelli M et al (2011) Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. PLoS ONE 6(3):e17971
pubmed: 21423579
pmcid: 3058055
doi: 10.1371/journal.pone.0017971
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 45(5):675–688
pubmed: 15748844
doi: 10.1016/j.neuron.2005.01.040
Shekhar S, Yadav Y, Singh AP, Pradhan R, Desai GR, Dey AB et al (2018) Neuroprotection by ethanolic extract of Syzygium aromaticum in Alzheimer’s disease like pathology via maintaining oxidative balance through SIRT1 pathway. Exp Gerontol 110:277–283
pubmed: 29959974
doi: 10.1016/j.exger.2018.06.026
Halder S, Mehta AK, Kar R, Mustafa M, Mediratta PK, Sharma KK (2011) Clove oil reverses learning and memory deficits in scopolamine-treated mice. Planta Med 77(08):830–834
pubmed: 21157682
doi: 10.1055/s-0030-1250605
Durairajan SSK, Huang YY, Yuen PY, Chen LL, Kwok KY, Liu LF et al (2014) Effects of Huanglian-Jie-Du-Tang and its modified formula on the modulation of amyloid-β precursor protein processing in Alzheimer’s disease models. PLoS ONE 9(3):e92954
pubmed: 24671102
pmcid: 3966845
doi: 10.1371/journal.pone.0092954
Lu DY, Tang CH, Chen YH, Wei IH (2010) Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem 110(3):697–705
pubmed: 20512929
doi: 10.1002/jcb.22580
Wong LR, Tan EA, Lim MEJ, Shen W, Lian XL, Wang Y et al (2021) Functional effects of berberine in modulating mitochondrial dysfunction and inflammatory response in the respective amyloidogenic cells and activated microglial cells - in vitro models simulating Alzheimer’s disease pathology. Life Sci 1(282):119824
doi: 10.1016/j.lfs.2021.119824
Stockburger C, Gold VAM, Pallas T, Kolesova N, Miano D, Leuner K et al (2014) A cell model for the initial phase of sporadic Alzheimer’s disease. J Alzheimers Dis JAD 42(2):395–411
pubmed: 24898661
doi: 10.3233/JAD-140381
Gower AJ, Lamberty Y (1993) The aged mouse as a model of cognitive decline with special emphasis on studies in NMRI mice. Behav Brain Res 57(2):163–173
pubmed: 8117421
doi: 10.1016/0166-4328(93)90132-A
Batarseh YS, Mohamed LA, Al Rihani SB, Mousa YM, Siddique AB, El Sayed KA et al (2017) Oleocanthal ameliorates amyloid-β oligomers’ toxicity on astrocytes and neuronal cells: in vitro studies. Neuroscience 3(352):204–215
doi: 10.1016/j.neuroscience.2017.03.059
Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Gauthier S et al (2019) Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry 20(3):173–189
doi: 10.1080/15622975.2017.1308552
Tian X, Zhang L, Wang J, Dai J, Shen S, Yang L et al (2013) The protective effect of hyperbaric oxygen and Ginkgo biloba extract on Aβ25-35-induced oxidative stress and neuronal apoptosis in rats. Behav Brain Res 1(242):1–8
doi: 10.1016/j.bbr.2012.12.026
Thancharoen O, Limwattananon C, Waleekhachonloet O, Rattanachotphanit T, Limwattananon P, Limpawattana P (2019) Ginkgo biloba extract (EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer’s disease: a network meta-analysis. Drugs Aging 36(5):435–452
pubmed: 30937879
doi: 10.1007/s40266-019-00648-x
Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L et al (2019) Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321(13):1286–1294
pubmed: 30938796
pmcid: 6450276
doi: 10.1001/jama.2019.2000
Ortiz A, Sansinenea E (2023) Phenylpropanoid derivatives and their role in plants’ health and as antimicrobials. Curr Microbiol 80(12):380
pubmed: 37864088
doi: 10.1007/s00284-023-03502-x
Kolaj I, Imindu Liyanage S, Weaver DF (2018) Phenylpropanoids and Alzheimer’s disease: a potential therapeutic platform. Neurochem Int 1(120):99–111
doi: 10.1016/j.neuint.2018.08.001
Zhang XW, Chen JY, Ouyang D, Lu JH (2020) Quercetin in animal models of Alzheimer’s disease: a systematic review of preclinical studies. Int J Mol Sci 21(2):493
pubmed: 31941000
pmcid: 7014205
doi: 10.3390/ijms21020493
Ho CL, Kao NJ, Lin CI, Cross TWL, Lin SH (2022) Quercetin increases mitochondrial biogenesis and reduces free radicals in neuronal SH-SY5Y cells. Nutrients 14(16):3310
pubmed: 36014814
pmcid: 9414536
doi: 10.3390/nu14163310
Paula PC, Angelica Maria SG, Luis CH, Gloria Patricia CG (2019) Preventive effect of quercetin in a triple transgenic Alzheimer’s disease mice model. Mol Basel Switz 24(12):2287
Tong-un T, Wannanon P, Wattanathorn J, Phachonpai W (2010) Cognitive-enhancing and antioxidant activities of quercetin liposomes in animal model of Alzheimer’s disease. OnLine J Biol Sci 10(2):84–91
doi: 10.3844/ojbsci.2010.84.91
Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F et al (2014) Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies. ScientificWorldJournal 2014:174282
pubmed: 24578620
pmcid: 3919104
doi: 10.1155/2014/174282
Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G et al (2016) Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br J Nutr 115(3):449–465
pubmed: 26652155
doi: 10.1017/S0007114515004687
Berry A, Collacchi B, Masella R, Varì R, Cirulli F (2021) Curcuma longa, the “golden spice” to counteract neuroinflammaging and cognitive decline—what have we learned and what needs to be done. Nutrients 13(5):1519
pubmed: 33946356
pmcid: 8145550
doi: 10.3390/nu13051519
Chen M, Du ZY, Zheng X, Li DL, Zhou RP, Zhang K (2018) Use of curcumin in diagnosis, prevention, and treatment of Alzheimer’s disease. Neural Regen Res 13(4):742–752
pubmed: 29722330
pmcid: 5950688
doi: 10.4103/1673-5374.230303
Liu H, Li Z, Qiu D, Gu Q, Lei Q, Mao L (2010) The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 485(2):83–88
pubmed: 20727383
doi: 10.1016/j.neulet.2010.08.035
Valera E, Dargusch R, Maher PA, Schubert D (2013) Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer’s disease. J Neurosci Off J Soc Neurosci 33(25):10512–10525
doi: 10.1523/JNEUROSCI.5183-12.2013
Shabbir U, Rubab M, Tyagi A, Oh DH (2021) Curcumin and its derivatives as theranostic agents in Alzheimer’s disease: the implication of nanotechnology. Int J Mol Sci 22(1):196
doi: 10.3390/ijms22010196
Ding L, Meng Y, Zhang HY, Yin WC, Yan Y, Cao YP (2017) Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice. Neurosci Res 119:7–14
pubmed: 28111220
doi: 10.1016/j.neures.2017.01.003
Li B, Liang F, Ding X, Yan Q, Zhao Y, Zhang X et al (2019) Interval and continuous exercise overcome memory deficits related to β-Amyloid accumulation through modulating mitochondrial dynamics. Behav Brain Res 376:112171
pubmed: 31445975
doi: 10.1016/j.bbr.2019.112171
Sutherland RJ, McDonald RJ (1990) Hippocampus, amygdala, and memory deficits in rats. Behav Brain Res 37(1):57–79
pubmed: 2310495
doi: 10.1016/0166-4328(90)90072-M
Akhtar A, Dhaliwal J, Sah SP (2021) 7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance. Psychopharmacology 238(7):1991–2009
pubmed: 33774703
doi: 10.1007/s00213-021-05826-7
Talboom JS, Velazquez R, Oddo S (2015) The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease. NPJ Aging Mech Dis 1:15008
pubmed: 28721257
pmcid: 5514987
doi: 10.1038/npjamd.2015.8
Siegmund SE, Yang H, Sharma R, Javors M, Skinner O, Mootha V et al (2017) Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet 26(23):4588–4605
pubmed: 28973153
pmcid: 5886265
doi: 10.1093/hmg/ddx341
Koushki M, Amiri-Dashatan N, Ahmadi N, Abbaszadeh H, Rezaei-Tavirani M (2018) Resveratrol: a miraculous natural compound for diseases treatment. Food Sci Nutr 6(8):2473–2490
pubmed: 30510749
pmcid: 6261232
doi: 10.1002/fsn3.855
Zhou DD, Luo M, Huang SY, Saimaiti A, Shang A, Gan RY et al (2021) Effects and mechanisms of resveratrol on aging and age-related diseases. Oxid Med Cell Longev 2021:9932218
pubmed: 34336123
pmcid: 8289612
doi: 10.1155/2021/9932218
Sousa JCE, Santana ACF, MagalhÃes GJP (2020) Resveratrol in Alzheimer’s disease: a review of pathophysiology and therapeutic potential. Arq Neuropsiquiatr 78(8):501–511
pubmed: 32520230
doi: 10.1590/0004-282x20200010
Ma X, Sun Z, Liu Y, Jia Y, Zhang B, Zhang J (2013) Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia. Neural Regen Res 8(22):2050–2059
pubmed: 25206513
pmcid: 4146064
Ferreira AFF, Binda KH, Singulani MP, Pereira CPM, Ferrari GD, Alberici LC et al (2020) Physical exercise protects against mitochondria alterations in the 6-hidroxydopamine rat model of Parkinson’s disease. Behav Brain Res 1(387):112607
doi: 10.1016/j.bbr.2020.112607
Singulani MP, De Paula VJR, Forlenza OV (2021) Mitochondrial dysfunction in Alzheimer’s disease: therapeutic implications of lithium. Neurosci Lett 24(760):136078
doi: 10.1016/j.neulet.2021.136078
Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry J Ment Sci 198(5):351–356
doi: 10.1192/bjp.bp.110.080044
De-Paula VJ, Gattaz WF, Forlenza OV (2016) Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar Disord 18(8):692–695
pubmed: 27882645
doi: 10.1111/bdi.12449
Undi RB, Gutti U, Gutti RK (2017) LiCl regulates mitochondrial biogenesis during megakaryocyte development. J Trace Elem Med Biol Organ Soc Miner Trace Elem GMS 39:193–201
doi: 10.1016/j.jtemb.2016.10.003
Ding XW, Robinson M, Li R, Aldhowayan H, Geetha T, Babu JR (2021) Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer’s disease. Pharmacol Res 171:105783
pubmed: 34302976
doi: 10.1016/j.phrs.2021.105783
Szeto HH (2006) Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 8(3):E521–E531
pubmed: 17025271
pmcid: 2761060
doi: 10.1208/aapsj080362
Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB et al (1996) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 17(777):57–64
doi: 10.1111/j.1749-6632.1996.tb34401.x
Lampinen R, Belaya I, Boccuni I, Kanninen TMKM, Lampinen R, Belaya I et al (2017) Mitochondrial function in Alzheimer’s disease: focus on astrocytes. In: Astrocyte - physiology and pathology [Internet]. IntechOpen.[cited 2024 May 5]. Available from: https://www.intechopen.com/chapters/58306
Steele HE, Horvath R, Lyon JJ, Chinnery PF (2017) Monitoring clinical progression with mitochondrial disease biomarkers. Brain 140(10):2530–2540
pubmed: 28969370
pmcid: 5841218
doi: 10.1093/brain/awx168
Murphy MP, Hartley RC (2018) Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov 17(12):865–886
pubmed: 30393373
doi: 10.1038/nrd.2018.174
Wojsiat J, Laskowska-Kaszub K, Mietelska-Porowska A, Wojda U (2017) Search for Alzheimer’s disease biomarkers in blood cells: hypotheses-driven approach. Biomark Med 11(10):917–931
pubmed: 28976776
doi: 10.2217/bmm-2017-0041
Chalmers S, Caldwell ST, Quin C, Prime TA, James AM, Cairns AG et al (2012) Selective uncoupling of individual mitochondria within a cell using a mitochondria-targeted photoactivated protonophore. J Am Chem Soc 134(2):758–761
pubmed: 22239373
doi: 10.1021/ja2077922
Logan A, Pell VR, Shaffer KJ, Evans C, Stanley NJ, Robb EL et al (2016) Assessing the mitochondrial membrane potential in cells and in vivo using targeted click chemistry and mass spectrometry. Cell Metab 23(2):379–385
pubmed: 26712463
pmcid: 4752821
doi: 10.1016/j.cmet.2015.11.014